Navigation Links
Coalition for Pulmonary Fibrosis Responds to News of Further Review of Pirfenidone By FDA

Decision Marks Delay in Potential First Treatment for Deadly Disease

SAN JOSE, Calif., May 4 /PRNewswire-USNewswire/ -- The Coalition for Pulmonary Fibrosis (CPF), representing tens of thousands of patients, is responding to the news that the FDA chose to ask for further study of Pirfenidone, which will delay potential approval of the first drug in the treatment of Pulmonary Fibrosis (PF), a lethal lung disease that is irreversible, progressive and deadly in an average of three years.  On March 9, 2010, an FDA Advisory Committee recommended approval of the drug by the FDA. 

"This news is disappointing for the Pulmonary Fibrosis patient community," said Mishka Michon, CEO of the CPF.  "Although the drug is not seen as a cure, it offers the first-ever option for treatment and some hope for these dying patients.  This is a setback for those patients who are anxious to gain access to this treatment now. We look forward to results of further review of the drug by the FDA.  We are hopeful that more attention to the disease will come and much will be learned that will encourage even more companies to research PF.  The need is profound and urgent."

Pulmonary Fibrosis is a disease that causes scarring in the lungs and renders them unable to exchange life sustaining blood oxygen. The disease strikes randomly, putting everyone at risk, and the causes of PF are largely unknown.

Important Facts about Pulmonary Fibrosis (PF):

  • 40,000 people will die from PF this year, the same number that is claimed by breast cancer.
  • Very few Americans have heard of Pulmonary Fibrosis (PF), but the deadly lung disease characterized by progressive and massive scarring in the lungs affects 128,000 Americans and there are no proven causes and no cure.  
  • The average life expectancy from diagnosis to death is just three years.  About 48,000 people will be diagnosed this year.  
  • PF Prevalence is increasing – 156% in the past seven years.  The need has never been greater for increased awareness, education, advocacy and research.
  • The Coalition for Pulmonary Fibrosis (CPF) is the preeminent patient and physician resource for Pulmonary Fibrosis.  [, 888-222-8541]

The CPF has long advocated on behalf of researchers and patients for accelerated research efforts to treat and cure PF, both in terms of drug development efforts by the pharmaceutical industry and research funded by the National Institutes of Health (NIH). With more than 23,000 members nationwide, the CPF is the largest nonprofit organization in the U.S. dedicated to advocating for those with PF.

The CPF is available to help members of the media with background information on PF, to provide comment on the delay of the drug and to provide interviews with CPF leaders and with patients affected by the disease.  Additional information and background on the CPF and the disease is available on the CPF website at  The CPF funds research primarily through a partnership with the American Thoracic Society, and has directly funded emerging research at several of the nation's leading centers for the treatment of PF including the University of Chicago, University of Michigan, and the David Geffen School of Medicine at UCLA.

About Pulmonary Fibrosis (PF)

Pulmonary Fibrosis (PF) is a lung disorder characterized by a progressive scarring – known as fibrosis -- and deterioration of the lungs, which slowly robs its victims of their ability to breathe. Approximately 128,000 Americans suffer from PF, and there is currently no known cause or cure. An estimated 48,000 new cases are diagnosed each year. PF is difficult to diagnose and an estimated two-thirds of patients die within five years of diagnosis.  Sometimes PF can be linked to a particular cause, such as certain environmental exposures, chemotherapy or radiation therapy, residual infection, or autoimmune diseases such as scleroderma or rheumatoid arthritis. However, in many instances, no known cause can be established. When this is the case, it is called idiopathic pulmonary fibrosis (IPF).

About the CPF

The CPF is a 501©(3) nonprofit organization, founded in 2001 to accelerate research efforts leading to a cure for pulmonary fibrosis (PF), while educating, supporting, and advocating for the community of patients, families, and medical professionals fighting this disease. The CPF funds promising research into new approaches to treat and cure PF; provides patients and families with comprehensive education materials, resources, and hope; serves as a voice for national advocacy of PF issues; and works to improve awareness of PF in the medical community as well as the general public. The CPF's nonprofit partners include many of the most respected medical centers and healthcare organizations in the U.S. With more than 23,000 members nationwide, the CPF is the largest nonprofit organization in the U.S. dedicated to advocating for those with PF. For more information please visit or call (888) 222-8541.

SOURCE Coalition for Pulmonary Fibrosis
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AIDS Vaccine Advocacy Coalition Voices Disappointment in Trial Result
2. AIDS Vaccine Advocacy Coalition Calls for AIDS Vaccine Field to Work Together to Analyze STEP Study Data and Determine Best Course to Move Forward
3. Childhood Influenza Immunization Coalition Encourages Vaccination Throughout the Influenza Season
4. Cancer Cure Coalition Proposes Major Changes at the FDA
5. Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients
6. CDC Foundation Launches Viral Hepatitis Action Coalition
7. Coalition for a Competitive Pharmaceutical Market Runs Ads Stating Congress Is Giving Greatest Holiday Gift of All to Brand Pharmaceutical Companies
8. Amoena and Young Survival Coalition Celebrate Breast Cancer Survivors With Contest and Cruise
9. Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension
10. Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007
11. Study Shows Need to Test More COPD and Asthma Patients for Underdiagnosed Pulmonary Disease
Post Your Comments:
(Date:11/26/2015)... 2015 Research and Markets ( ) ... Care Market by Type (Dressings, Therapy Devices, Active Wound ... Out-Patient Facility), and Geography - Global Forecast to 2020" ... --> --> The purpose of this ... of the global advanced wound care market. It involves ...
(Date:11/26/2015)... , November 26, 2015 ... of the "Radioimmunoassay Market by Type ... Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application ... Forecast to 2020" report to their ... announced the addition of the "Radioimmunoassay ...
(Date:11/25/2015)... 2015  The American Academy of Pediatrics (AAP), ... the March of Dimes cheered today,s signature into ... Act of 2015 (S.799), which takes much-needed ... exposed to drugs, such as opioids, and to ... three organizations have worked together leading advocacy efforts ...
Breaking Medicine Technology:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Dr. John ... to learn more about hair loss treatment with the Capillus272™ Pro laser therapy cap. ... solution for thicker and fuller hair, without the need for surgery, prescription pills, or ...
(Date:11/25/2015)... TX (PRWEB) , ... November 25, 2015 , ... For ... the companies’ “ Two Organizations, One Beat ” campaign. The partnership between the two ... services to aid in MAP International’s cause. , MAP International was founded in 1954 ...
(Date:11/25/2015)... ... 25, 2015 , ... Dental professionals who would like to become more proficient ... attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will be held ... the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud ...
(Date:11/25/2015)... , ... November 25, 2015 , ... The McHenry County ... recent successful appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. ... Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, ...
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, ... facial plastic surgeon specializing in both surgical and non-surgical treatments, announced the expansion ... at Hobgood Facial Plastic Surgery. , Highly trained and nationally recognized for ...
Breaking Medicine News(10 mins):